Pfizer/Merck KGaA scrap a pivotal trial, partly because it tested Bavencio against what is no longer the relevant standard of care.
Probiodrug grabs $15m, but it will need more to fund phase IIb development of its Alzheimer’s candidate, PQ912.
The battle for dominance of the transcatheter aortic valve market has shifted to new territory. And once again, Edwards Lifesciences is winning.
For Urovant, beating placebo in a pivotal trial of vibegron was the easy part.
Business development decisions have started the clock on a financial time bomb set to go off within the next three months.
No genetic correlation was seen with Merck & Co's CETP inhibitor, but Dalcor believes that things will be different for dalcetrapib.
Another vast trial is on the cards for Apple’s ECG, and ought to yield more meaningful data.
As approval decisions near, further data fail to answer lingering questions about Esperion's bempedoic acid and Amarin's Vascepa.
The long overdue readout of a pivotal birch pollen allergy vaccine trial draws a blank for the beleaguered UK company.
Dermira hopes that lebrikizumab can beat Dupixent, while Conatus tries to overcome an earlier Nash setback.
With few pipeline catalysts this year the pressure is growing on Lundbeck's new chief executive, Deborah Dunsire, to deliver a deal. But the company only has $5bn to…
Will the Apple Heart Study allow early detection of arrhythmias, or drive the worried well to doctors unnecessarily? For Irhythm Technologies, either is a good outcome.
Targeting a mechanism of resistance to first-generation BTK inhibitors has caught the attention of biotechs like Arqule, which claimed a major success last week.
An Icer white paper provides ammunition for both PBMs and pharma before the next Capitol Hill hearing.
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Fears about flattening Opdivo sales were surely a major driver for Bristol's move for Celgene. To keep growing the checkpoint inhibitor needs some big clinical wins.
The UK ortho and woundcare group might yet pounce on Nuvasive.
Six months after floating, Urovant is gearing up to release pivotal data on its most advanced overactive bladder project.
Amarin and Esperion get a chance to reinforce their lipid-lowering candidates, while a Bayer heart failure project gets a high-profile slot despite its discontinuation.
Axovant is the latest company to benefit from excitement over gene therapy data in small numbers of patients.